SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New lupus drug tested for Long-Term safety in large study
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who completed an earlier study will continue receiving litifilimab injections every 4 weeks for up to 3 years, while also taking their usual lupus medications. Res…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New lupus drug candidate enters first human safety tests
Disease control OngoingThis early-stage study tests an experimental injection called SG301 in 48 people. First, healthy volunteers receive a single dose to check safety. Then, people with systemic lupus erythematosus (SLE) receive multiple doses. The main goal is to see if the drug is safe and how the …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New lupus drug candidate enters first human safety tests
Disease control OngoingThis early-stage study tests a new drug called KK4277 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to see if the drug is safe and how the body processes it. About 157 participants will receive either the drug or a placebo. This is a first step to see…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses specially engineered immune cells from a donor to target and attack faulty B cells that drive the disease. The main goals are …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC